Spark Therapeutics

166 articles with Spark Therapeutics

• Spark Therapeutics Enters Into Strategic Collaboration with Neurochase for Use of Proprietary Delivery Technology for CNS Disorders

  1/27/2023

  Spark Therapeutics and Neurochase, a company specializing in the development of scalable therapeutic strategies and enabling technology for direct delivery to the central nervous system (CNS), today announced a strategic collaboration to develop Neurochase’s proprietary delivery technology for use with selected gene therapies for rare diseases in CNS.

• Spark Therapeutics Announces Updated Phase 1/2 Study Results Supporting the Durability of Investigational Gene Therapy SPK-8011 in Patients With Hemophilia A

  12/12/2022

  Spark Therapeutics, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and a fully integrated gene therapy company today announced updated multi-year results from its Phase 1/2 clinical trial of investigational SPK-8011 for patients with hemophilia A.

• 

  Nanoscope Zooms in on Retinitis Pigmentosa and Stargardt Disease at ASRS

  7/12/2022

  Nanoscope Therapeutics will make two presentations at the 2022 ASRS meeting on their gene therapy programs to treat degenerative retinal diseases, retinitis pigmentosa and Stargardt disease.
• 

  Dark Horse Consulting Submits Guidance on Gene Therapy Safety

  5/17/2022

  Dark Horse Consulting Group (DHC), based in Walnut Creek, Calif., submitted proposed draft guidance to the FDA for gene therapy safety.
• 

  Drug Price Watchdog Calls Bluebird Bio’s $2.1 Million Gene Therapy Cost-Effective

  4/14/2022

  Drug pricing watchdog ICER issued a draft report on bluebird bio’s gene therapy betibeglogene autotemcel for beta-thalassemia. The report touted the therapy's cost-effectiveness.
• 

  World's First Gene Therapy, IPO, Major Merger - Spark's CEO Leaves a Legacy

  2/24/2022

  Jeffrey D. Marrazzo, the co-founder of Spark Therapeutics, is stepping down as CEO of the company. The current COO, Ron Philip, will replace him.

• Spark Therapeutics Announces Departure of CEO and Founder Jeff Marrazzo; COO Ron Philip Named as Successor

  2/23/2022

  Spark Therapeutics, a member of the Roche Group and a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, announced that Ron Philip, Spark’s chief operating officer, will succeed co-founder Jeffrey D. Marrazzo as chief executive officer.

• 

  Movers & Shakers, Jan. 7

  1/7/2022

  With the turn of the calendar, biopharma and life sciences organizations have bolstered their leadership teams and board with these Movers & Shakers.

• Spark Therapeutics to Invest $575M in New 500k Square Foot State-of-the-Art Gene Therapy Innovation Center on Drexel’s University City Campus

  12/17/2021

  Spark Therapeutics today announced plans to invest an initial $575M in the creation of a new, state-of-the-art gene therapy innovation center on Drexel University’s campus in the heart of Philadelphia’s University City neighborhood.

• Spark Therapeutics Updated SPK-8011 Data from Phase 1/2 Study Shows Multi-Year, Durable Factor VIII (FVIII) Expression that Significantly Reduced Bleeding in Hemophilia A Patients

  11/17/2021

  Spark Therapeutics, a member of the Roche Group and a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, announced data from its Phase 1/2 clinical trial of investigational SPK-8011 in hemophilia A.

• 

  Bespoke Consortium Born to Bring Gene Therapy to Rare Diseases

  10/28/2021

  Collaboration is key to faster breakthroughs. The NIH, FDA, and 15 private organizations have announced they are joining forces for the sake of the 30 million Americans suffering from a rare disease.

• Spark Therapeutics and CombiGene Enter into Exclusive, Global Licensing Agreement for Gene Therapy Candidate CG01

  10/12/2021

  Spark Therapeutics and CombiGene AB (‘CombiGene’) today announced the signing of an exclusive collaboration and licensing agreement for CombiGene’s CG01 project, an investigational gene therapy which aims to treat drug resistant focal epilepsy.

• 

  Companies Enter Licensing Agreements to Expand Gene Therapy Programs

  10/12/2021

  Takeda entered into a licensing pact with Poseida, Spark entered into a licensing agreement with CombiGene AB, while BridgeBio Pharma announced plans for its second annual R&D Day. 
• 

  Rejuvenate Bio is Reversing Age-Related Diseases to Increase Healthspan

  10/6/2021

  Unlike most companies addressing the diseases associated with aging, Rejuvenate Bio tackles multiple cardiac, metabolic and renal issues at once.
• 

  Say it Ain’t So, Glaxo. Company to Leave Research Triangle Park Campus

  10/5/2021

  With the planned departure from its 561,652-square-foot RTP campus, GSK will reduce its geographical footprint, but not its staff.
• 

  Philadelphia Bursting at the Seams as Biopharma Hub Status Grows

  10/1/2021

  As the city rapidly develops as a biopharma hub, wet lab space is rapidly dwindling.
• 

  Spark Founders Launch Opus Genetics to Tackle Rare Forms of Blindness

  9/22/2021

  The startup’s initial focus will be on rare blindness conditions affecting pediatric patients.

• NeuExcell Therapeutics and Spark Therapeutics Announce Research Collaboration Agreement to Develop a Novel Gene Therapy for Huntington's Disease

  9/7/2021

  NeuExcell Therapeutics and Spark Therapeutics, a member of the Roche Group announced a gene therapy collaboration aimed at developing a safe and effective treatment for patients suffering from Huntington's Disease.

• 

  FDA Summit on Gene Therapy Risks Proves Timely

  9/7/2021

  The oncogenicity and neurotoxicity risks of AAVs and possible mitigation strategies were the primary focus on Thursday.
• 

  Collaboration Sparks Hope for Huntington's Disease Cure

  9/7/2021

  ​The collaboration between Spark and NeuExcell increased the hope for Huntington's disease cure in near future. This is going to be a great relief for all the patients.